Medicines Formulary

Reports

Drug name	NICE TAs	Comments
L-ornithine L-aspartate 5gm/10ml injection
Loteprednol etabonate 0.5% eye drops
Lumacaftor-ivacaftor (Orkambi®)	TA398 - Lumacaftor-ivacaftor for treating cystic fibrosis homozygous for the F508del mutation	NHSE commissioning statement
Lusutrombopag (Mulpleo®)	TA617 - Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Magnesium 150mg tablets (as citrate)
Magnesium sulphate injection
Manchester bleaching cream		Unlicensed special
Mannitol infusion		Hospital only
Mannitol inhalation (Bronchitol®)	TA266 - Mannitol dry powder for inhalation for treating cystic fibrosis	Hospital only
Mecasermin Increlex®		NHSE commissioned

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.